As of the end of March 2025, the company (TNGX, Financial) reported it had $216.7 million in cash, cash equivalents, and marketable securities. This financial position is projected to sustain its operational activities until the first quarter of 2027. The prolonged financial runway is largely attributed to a strategic scaling back of its preclinical pipeline and target discovery projects, accompanied by a reduction in research staff. Additionally, the company has postponed certain clinical combination studies, particularly those intended to evaluate the compatibility of TNG462 with existing standard treatment methodologies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Tango Therapeutics Inc (TNGX, Financial) is $11.00 with a high estimate of $16.00 and a low estimate of $8.00. The average target implies an upside of 864.91% from the current price of $1.14. More detailed estimate data can be found on the Tango Therapeutics Inc (TNGX) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Tango Therapeutics Inc's (TNGX, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Tango Therapeutics Inc (TNGX, Financial) in one year is $4.55, suggesting a upside of 299.12% from the current price of $1.14. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Tango Therapeutics Inc (TNGX) Summary page.
